Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Sarcoma 1Renal Insufficiency 1Penile Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Melanoma 1Mastocytosis, Systemic 1Mast Cell Activation Disorders 1Leukemia, Mast-Cell 1Glioma 1Gastrointestinal Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1

Interventions

fludarabine 2ripretinib 1pembrolizumab 1fludarabine phosphate 1bintrafusp alfa protein, human 1Therapeutics 1Tetrahydrouridine 1Stem Cell Transplantation 1Sirolimus 1Psychiatric Rehabilitation 1Mesna 1Melphalan 1Decitabine 1Cyclophosphamide 1Celecoxib 1Busulfan 1Azacitidine 1Amplified Fragment Length Polymorphism Analysis 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Germ Cell and Embryonal × ripretinib × Dermatologic × Clear all
NCT02571036 2023-12-13

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Deciphera Pharmaceuticals, LLC

Phase 1 Completed
282 enrolled
CNSDermatologicGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmSarcomaThoracic

Mast Cell Activation Disorders, Carcinoma, Non-Small-Cell Lung, Glioma, Leukemia, Mast-Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Penile Neoplasms, Sarcoma, Mastocytosis, Systemic, Gastrointestinal Stromal Tumors, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡